You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
The levonorgestrel intrauterine system: effective non-surgical treatment for heavy menstrual bleeding
  1. Andrew M Kaunitz
  1. Department of Obstetrics and Gynecology, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, USA
  1. Correspondence to Professor Andrew M Kaunitz
    Department of Obstetrics and Gynecology, University of Florida College of Medicine-Jacksonville, 653-1 W 8th Street, Jacksonville, FL 32209, USA; andrew.kaunitz{at}jax.ufl.edu

https://doi.org/10.1136/eb-2013-101275

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Gupta J, Kai J, Middleton L, et al. ECLIPSE Trial Collaborative Group. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med 2013;368:128–37.OpenUrlCrossRefPubMedWeb of Science

    Context

    Heavy menstrual bleeding (HMB), which has become the preferred terminology to describe excess menstrual bleeding or menorrhagia,1 is prevalent among reproductive age women, negatively impacts quality of life, and represents a common reason for women to seek medical care and undergo gynaecological surgery. Although numerous comparative trials have demonstrated the efficacy of the levonorgestrel-releasing intrauterine system (LNG-IUS) in treating HMB, in general, these studies have been of 1 year or less in duration and have included small numbers of participants.2

    Methods

    Gupta and colleagues randomised 571 women in the UK who reported HMB to placement of an LNG-IUS or ‘usual medical treatment’ and followed the participants …

    View Full Text

    Footnotes

    • Competing interests AMK consults with Bayer, Merck, Teva and Agile and his institution has received research funding from Bayer. He also receives royalties from Up-To-Date e-textbook for chapters on contraception. He has also has received payment for development of Continuing Medical Education Programs regarding IUDs funded by Teva and Bayer.